Literature DB >> 7720039

Is episialin/MUC1 involved in breast cancer progression?

J Hilkens1, H L Vos, J Wesseling, M Boer, J Storm, S van der Valk, J Calafat, C Patriarca.   

Abstract

Episialin, also designated MUC1, CA 15-3 antigen and PEM, is an established serum marker for breast cancer. Its function and possible involvement in tumor progression has not yet been completely established. The molecule is an extended rod-like molecule protruding high above the cell surface. It is often highly overexpressed in breast cancer relative to normal breast epithelium cells. Overexpression of episialin on cells in vitro reduces cell-cell and cell-extracellular matrix adhesion, because the rod-like molecule masks the adhesion receptors. Episialin also exerts its anti-adhesion effect in vivo. In certain human tumors, where episialin was present at the basal side of the cell, abnormal contacts between the plasma membrane and the stroma were observed. As a consequence of its anti-adhesion properties, episialin overexpression reduces the sensitivity of the cells for cytotoxic lymphocytes. This might be one of the reasons why episialin transfected cells are more potent to form experimental metastases after i.v. injection into nude mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720039     DOI: 10.1016/0304-3835(94)03674-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  A cell surface mucin specifically expressed in the midgut of the malaria mosquito Anopheles gambiae.

Authors:  Z Shen; G Dimopoulos; F C Kafatos; M Jacobs-Lorena
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

Review 3.  Tissue architecture: the ultimate regulator of epithelial function?

Authors:  C Hagios; A Lochter; M J Bissell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

Review 4.  Invasive micropapillary carcinoma: a distinct type of adenocarcinomas in the gastrointestinal tract.

Authors:  Katarzyna Guzińska-Ustymowicz; Katarzyna Niewiarowska; Anna Pryczynicz
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

Review 5.  Membrane-tethered mucins have multiple functions on the ocular surface.

Authors:  Bharathi Govindarajan; Ilene K Gipson
Journal:  Exp Eye Res       Date:  2010-03-16       Impact factor: 3.467

Review 6.  The role of cadherin-mediated adhesion in breast cancer.

Authors:  C L Sommers
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

Review 7.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.

Authors:  Pawel Ciborowski; Olivera J Finn
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

9.  A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis.

Authors:  Steven T Huyn; Jeremy B Burton; Makoto Sato; Michael Carey; Sanjiv S Gambhir; Lily Wu
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

10.  Intracellular MUC1 peptides inhibit cancer progression.

Authors:  Benjamin G Bitler; Ina Menzl; Carmen L Huerta; Barbara Sands; Wendy Knowlton; Andrew Chang; Joyce A Schroeder
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.